Combined therapy with gemcitabine hydrochloride and nanoparticle albumin-bound paclitaxel enabled resection in a patient with unresectable locally advanced pancreatic cancer

[1]  T. Conroy,et al.  FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. , 2016, The Lancet. Oncology.

[2]  H. Ueno,et al.  Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer , 2016, Cancer Chemotherapy and Pharmacology.

[3]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[4]  A. Maitra,et al.  Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[6]  J. Furuse,et al.  Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506. , 2010, Japanese journal of clinical oncology.

[7]  S. Song,et al.  Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer , 2009, Cancer Chemotherapy and Pharmacology.

[8]  H. Einsele,et al.  Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Labianca,et al.  Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  W. Miller,et al.  Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Ayuso,et al.  Preoperative Staging and Tumor Resectability Assessment of Pancreatic Cancer: Prospective Study Comparing Endoscopic Ultrasonography, Helical Computed Tomography, Magnetic Resonance Imaging, and Angiography , 2004, American Journal of Gastroenterology.

[12]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  ほか,et al.  化学療法（GEM＋S-1）により根治切除可能となった局所進行膵癌の1例 , 2015 .

[14]  N. Yonemoto,et al.  A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer. , 2013, International journal of radiation oncology, biology, physics.